Page 436 - شرور شركات الأدوية

‫ﴍور ﴍﻛﺎت اﻷدوﻳﺔ‬

(112) Rothman KJ, Evans S (2005) Extra scrutiny for industry funded
trials. BMJ 331: 1350-1351.

(113) Wager E, Mhaskar R, Warburton S, Djulbegovic B (2010) JAMA
Published Fewer Industry-Funded Studies after Introducing a Require-
ment for Independent Statistical Analysis. PLoS ONE 5(10): e13591.
doi:10.1371/journal.pone.0013591

(114) Chalmers TC, Frank CS, Reitman D. Minimizing the Three Stages
of Publication Bias. JAMA. 1990 Mar 9;263(10):1392–5.

(115) Samena Chaudhry et al., ‘Does declaration of competing inter-
ests affect readers’ perceptions? A randomised trial,’ BMJ 325, no. 7377
(December 14, 2002): 1391-1392. (below).

(116) Reporting of Conflicts of Interest in Meta-analyses of Tri-
als of Pharmacological Treatments. JAMA. 2011;305(10):1008–1017. doi:
10.1001/jama.2011.257.

(117) Loewenstein G, Sah S, Cain DM. The Unintended Consequences
of Conflict of Interest Disclosure. JAMA. 2012 Feb 15;307(7):669-70.

(118) Cain, D. M., Loewenstein, G., & Moore, D. A. (2005). The dirt on
coming clean: perverse effects of disclosing conflicts of interest. Journal
of Legal Issues, 34, 1e25.

(119) Campbell EG, Weissman JS, Ehringhaus S et al. Institutional aca-
demic industry relationships. JAMA 2007;298:1779–86.

(120) http://www.propublica.org/series/dollars-for-docs.
(121) http://www.propublica.org/article/doctors-dine-on-drug-
companies-dime.
(122) http://www.propublica.org/article/dollars-for-docs-sparks-
policy-rewrite-at-colorado-teaching-hospitals.
(123) http://www.propublica.org/article/medical-schools-plug-hol
es-in-conflict-of-interest-policies.

436